Page last updated: 2024-12-07

l 158809

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

L 158809: RN & structure given in first source; angiotensin receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID183134
CHEMBL ID7550
SCHEMBL ID683357
MeSH IDM0193006

Synonyms (27)

Synonym
l-158809
l 158809
L004397
CHEMBL7550 ,
2-ethyl-5,7-dimethyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
2-ethyl-5,7-dimethyl-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine(l-158809)
2-ethyl-5,7-dimethyl-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine (l158809)
2-ethyl-5,7-dimethyl-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine
2-ethyl-5,7-dimethyl-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine
2-ethyl-5,7-dimethyl-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine (l-158809)
bdbm50009718
133240-46-7
2-ethyl-5,7-dimethyl-3-((4-(2-(2h-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine
3h-imidazo(4,5-b)pyridine, 2-ethyl-5,7-dimethyl-3-((2'-(2h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
[3h]l-158,809
[3h]-l158809
gtpl3939
[3h]l158809
2-ethyl-5,7-dimethyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[5,4-b]pyridine
SCHEMBL683357
YFWXFHNZGKNDBC-UHFFFAOYSA-N ,
2-ethyl-5,7-dimethyl-3-[(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl]-3h-imidazo[4,5-b]pyridine
DTXSID00928018
2-ethyl-5,7-dimethyl-3-{[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-3h-imidazo[4,5-b]pyridine
3-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethyl-5,7-dimethyl-3h-imidazo[4,5-b]pyridine
2-ethyl-5,7-dimethyl-3-[2'-(1h-tetrazole-5-yl)biphenyl-4-ylmethyl]-3h-imidazo[4,5-b]pyridine
AKOS040745965

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compounds are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists."( Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Berellini, G; Cruciani, G; Mannhold, R, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" The peak concentration was 42 +/- 42 ng/ml at 30 min, and the bioavailability was 32."( Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys.
Colletti, AE; Krieter, PA,
)
0.13
" Although 71 was active orally only at a 10-fold higher dose level, good oral bioavailability was demonstrated for a monoacidic analogue 62."( Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
Ashton, WT; Cantone, CL; Chang, LL; Chang, RS; Chen, TB; Faust, KA; Hutchins, SM; Lotti, VJ; MacCoss, M; Strelitz, RA, 1993
)
0.29
" Remarkably, the least permeable 7c showed both permeability and oral bioavailability (80%) higher than losartan, but its terminal half-life was shorter."( Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
Anzini, M; Cappelli, A; Caselli, G; Ferrari, F; Gallelli, A; Giordani, A; Giorgi, G; Giuliani, G; Makovec, F; Mennuni, L; Mohr, Gl; Nannicini, C; Peris, W; Valenti, S; Vomero, S, 2008
)
0.35
"6 nM) with partial PPARγ agonism (EC(50) = 212 nM, 31% max) and oral bioavailability in rat."( Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Bigge, CF; Casimiro-Garcia, A; Chen, J; Davis, JA; Dudley, DA; Edmunds, JJ; Ellis, T; Esmaeil, N; Filzen, GF; Flynn, D; Geyer, A; Heemstra, RJ; Jalaie, M; Ohren, JF; Ostroski, R; Schaum, RP; Stoner, C, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" L-162,782 acted as a powerful partial agonist, stimulating phosphatidylinositol turnover with a bell-shaped dose-response curve to 64% of the maximal level reached in response to angiotensin II."( Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.
Costa-Neto, CM; Greenlee, WJ; Hjorth, SA; Miyakawa, AA; Paiva, AC; Perlman, S; Rivero, RA; Schambye, HT; Schwartz, TW, 1997
)
0.3
" In vivo studies were evaluated by L-158,809 antagonist AT1 function versus the shift of the normal dose-response curve of blood pressure induced by Angiotensine II."( Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation.
Escher, E; Hildgen, P; Lacasse, FX; McMullen, JN; Pérodin, J; Phillips, NC, 1997
)
0.3
" In vivo studies with two different formulations show a strong shift of angiotensin II dose-response curve."( Improved activity of a new angiotensin receptor antagonist by an injectable spray-dried polymer microsphere preparation.
Escher, E; Hildgen, P; Lacasse, FX; McMullen, JN; Pérodin, J; Phillips, NC, 1997
)
0.3
" Nine male THM aged 20 weeks were assigned to each of a no-dosage group and an L-158,809 dosage group, and L-158,809 was administered for 8 weeks."( Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension.
Ishikawa, K; Kai, T; Kurooka, A; Shimada, S; Sugimura, K; Takenaka, T, 1998
)
0.3
" Uterine ANG II dose-response curves were repeated following administration of the ANG II type 2 receptor (AT(2)) antagonist PD-123319 and then repeated again in the presence of an ANG II type 1 receptor (AT(1)) antagonist L-158809."( Functional role of angiotensin II type 1 and 2 receptors in regulation of uterine blood flow in nonpregnant sheep.
Clark, KE; Greenberg, SG; Lambers, DS, 2000
)
0.31
" Incubation with ANGII (10(-9) and 10(-8) M) had no significant effect on the dose-response curve for insulin-stimulated [(3)H]2-deoxyglucose uptake."( Possible interactions between angiotensin II and insulin: effects on glucose and lipid metabolism in vivo and in vitro.
Donnelly, R; Gray, S; Idris, I; Patiag, D; Qu, X; Seale, JP; Wilkes, M, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)IC50 (µMol)0.00210.00040.15553.8000AID39505
Type-1A angiotensin II receptor Rattus norvegicus (Norway rat)Ki0.00040.00020.10251.7000AID39022
Type-1B angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00120.00040.13343.8000AID37687; AID39505
Type-1 angiotensin II receptorHomo sapiens (human)IC50 (µMol)0.00150.00020.09323.6000AID607037; AID711558
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)IC50 (µMol)0.00030.00010.09130.5000AID37549; AID568899
Type-2 angiotensin II receptorRattus norvegicus (Norway rat)IC50 (µMol)16.00040.00100.39573.3000AID38161; AID38276; AID38284; AID39505; AID39524
Type-2 angiotensin II receptorHomo sapiens (human)IC50 (µMol)0.00020.00010.02890.2000AID568926
Type-2 angiotensin II receptorHomo sapiens (human)Ki0.00040.00020.56507.7790AID39022
5-hydroxytryptamine receptor 1AMus musculus (house mouse)IC50 (µMol)0.00210.00210.35812.0000AID39505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)20.00000.00000.992210.0000AID607038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Type-1 angiotensin II receptorHomo sapiens (human)Affinity0.00050.00050.03150.2300AID243379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (119)

Processvia Protein(s)Taxonomy
regulation of cell growthType-1 angiotensin II receptorHomo sapiens (human)
kidney developmentType-1 angiotensin II receptorHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionType-1 angiotensin II receptorHomo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinType-1 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationType-1 angiotensin II receptorHomo sapiens (human)
Rho protein signal transductionType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationType-1 angiotensin II receptorHomo sapiens (human)
regulation of vasoconstrictionType-1 angiotensin II receptorHomo sapiens (human)
calcium-mediated signalingType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityType-1 angiotensin II receptorHomo sapiens (human)
low-density lipoprotein particle remodelingType-1 angiotensin II receptorHomo sapiens (human)
regulation of renal sodium excretionType-1 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
regulation of cell population proliferationType-1 angiotensin II receptorHomo sapiens (human)
symbiont entry into host cellType-1 angiotensin II receptorHomo sapiens (human)
regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of protein metabolic processType-1 angiotensin II receptorHomo sapiens (human)
cell chemotaxisType-1 angiotensin II receptorHomo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathwayType-1 angiotensin II receptorHomo sapiens (human)
blood vessel diameter maintenanceType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesisType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of CoA-transferase activityType-1 angiotensin II receptorHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processType-1 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-1 angiotensin II receptorHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
blood vessel remodelingType-2 angiotensin II receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensinType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressureType-2 angiotensin II receptorHomo sapiens (human)
brain renin-angiotensin systemType-2 angiotensin II receptorHomo sapiens (human)
cell surface receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messengerType-2 angiotensin II receptorHomo sapiens (human)
brain developmentType-2 angiotensin II receptorHomo sapiens (human)
regulation of blood pressureType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of heart rateType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of cell growthType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityType-2 angiotensin II receptorHomo sapiens (human)
regulation of metanephros sizeType-2 angiotensin II receptorHomo sapiens (human)
exploration behaviorType-2 angiotensin II receptorHomo sapiens (human)
nitric oxide-cGMP-mediated signalingType-2 angiotensin II receptorHomo sapiens (human)
angiotensin-activated signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
vasodilationType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionType-2 angiotensin II receptorHomo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
neuron apoptotic processType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of metanephric glomerulus developmentType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesisType-2 angiotensin II receptorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayType-2 angiotensin II receptorHomo sapiens (human)
inflammatory responseType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
angiotensin type I receptor activityType-1 angiotensin II receptorHomo sapiens (human)
angiotensin type II receptor activityType-1 angiotensin II receptorHomo sapiens (human)
protein bindingType-1 angiotensin II receptorHomo sapiens (human)
bradykinin receptor bindingType-1 angiotensin II receptorHomo sapiens (human)
protein heterodimerization activityType-1 angiotensin II receptorHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
angiotensin type II receptor activityType-2 angiotensin II receptorHomo sapiens (human)
protein bindingType-2 angiotensin II receptorHomo sapiens (human)
receptor antagonist activityType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
membraneType-1 angiotensin II receptorHomo sapiens (human)
plasma membraneType-1 angiotensin II receptorHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
plasma membraneType-2 angiotensin II receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID17957Apparent bioavailability after oral dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID243379Binding affinity for AT1 receptor2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID568899Binding affinity to angiotensin AT1 receptor in rabbit aortic rings2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID192970The compound was evaluated for the percentage of inhibition of A II pressor response in rat for intravenous administration1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID197549Percentage peak pressor response in rat after intravenous administration at a dose of 0.03 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID38276In vitro antagonist activity against angiotensin II receptor type 2 in rat midbrain using [125I]-Sar,Ile AII.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
AID22406Volume of distribution of the terminal phase (= CLp+ plasma elimination rate constant) after intravenous dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID167369Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID39505Binding affinity against AT1 receptor of rat adrenal cortical membranes1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.
AID37514Displacement of [1251][Sar1,IIe8]AII from rabbit aorta Angiotensin II receptor, type 11993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
AID234499Ratio of the of A II pressor responses in rat, p.o./i.v.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID38161In vitro antagonist activity against angiotensin II type 2 (AT2) receptor in rat midbrain using [125I]- Sar, Ile AII.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
AID24000Half-life period after oral dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID231153Ratio of the of A II pressor responses in dog, p.o./i.v.; ND= Not determined1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID22398Volume of distribution of central compartment (= dose+ plasma concentration at time zero) after intravenous dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID167537Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID37687Binding affinity for rat angiotensin II receptor, type 12004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
AID37542Potency to antagonize the ability of angiotensin II to contract rabbit aorta1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39047Inhibition of Angiotensin II induced contractions in rabbit aortic rings1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.
AID174386% decrease in blood pressure after 4 hours in male rats at a dose of 0.1 mg/kg by using Renal artery hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39503In vitro binding affinity for angiotensin II AT1 receptor in rabbit aorta1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID197552Percentage peak pressor response in rat after peroral administration at a dose of 0.03 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID56499The compound was evaluated for the percentage of inhibition of A II pressor response in dogs for intravenous administration1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID39360The compound was tested for inhibition of angiotensin II receptor induced pressor response in rat after intravenous administration.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID37519Inhibitory activity was evaluated against Angiotensin II receptor, type 1 in rabbit aorta1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID56383The compound was evaluated for the percentage of inhibition of A II pressor response in dog for peroral administration; ND= Not determined1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID15900Plasma clearance after intravenous dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID607038Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
AID23995Half-life period of compound after intravenous dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID38284Displacement of [1251][Sar1,IIe8]AII from rat midbrain angiotensin II (AT2) receptor1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
AID174388% decrease in blood pressure after 4 hours in male rats at a dose of 0.3 mg/kg by using Renal artery hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID174797The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg perol administration in conscious rats.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID18416Oral bioavailability was evaluated in rat by oral administration1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID22341Tmax value after oral dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID231155Ratio of the of A II pressor responses in rhesus monkey, p.o./i.v.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID176261Intravenous effective dose required for inhibition of Ang II pressor response in conscious rat1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID711558Antagonist activity at angiotensin 1 receptor2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID568926Binding affinity to angiotensin AT2 receptor2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID192958The compound was evaluated for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg intravenous administration in conscious rats.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID607039Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay relative to darglitazone2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
AID607037Displacement of [125I]Tyr4-Sar1,Ile8-Angiotensin II from human Angiotensin 1 receptor after 60 mins by scintillation counting2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
AID197554Percentage peak pressor response in rat after peroral administration at a dose of 0.3 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID174247% decrease in blood pressure after 4 hours at a dose of 1 mg/kg in male rats by using Furosemide-treated spontaneous hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39807In vitro antagonist activity against angiotensin II receptor type 1 in rabbit aorta using [125I]-Sar, Ile AII.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.
AID174250% decrease in blood pressure after 4 hours at a dose of 3 mg/kg in male rats by using Renal artery hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID174254% decrease in blood pressure after 4 hours in male rats at a dose of 0.03 mg/kg by using Renal artery hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39808In vitro antagonist activity against angiotensin II receptor type 1 in rabbit aorta using [125I]-Sar, Ile AII.1993Journal of medicinal chemistry, Dec-24, Volume: 36, Issue:26
Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.
AID330796Displacement of [125I]Sar1,Ile8-Ang2 from AT1 receptor in Wistar rat hepatic membrane2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID176434Oral effective dose required for inhibition of Ang II pressor response in conscious rat1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID18419Oral bioavailability was evaluated in rhesus monkey1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID125514The compound was evaluated for the percentage of inhibition of A II pressor response in rhesus monkey for peroral administration.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID195024pA2 value was evaluated against angiotensin II-induced aldosterone release in rat adrenal cortical cells1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID197550Percentage peak pressor response in rat after intravenous administration at a dose of 0.1 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID18415Oral bioavailability in rat1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID192959The compound was evaluated for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg perol administration in conscious rats.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID125515The compound was evaluated for the percentage of inhibition of A II pressor response in rhesus monkeys for intravenous administration1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID10481Area under curve after oral dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID174240% decrease in blood pressure after 24 hours at a dose of 1 mg/kg in male rats by using Furosemide-treated spontaneous hypertensive model1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39195Binding affinity towards Angiotensin receptor from rabbit aorta1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID174796The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg intravenous administration in conscious rats.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID192971The compound was evaluated for the percentage of inhibition of A II pressor response in rat for peroral administration.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID37549Inhibition of Angiotensin II receptor, type 11993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Excursions in drug discovery.
AID197553Percentage peak pressor response in rat after peroral administration at a dose of 0.1 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID39809Displacement of [125I]-Sar1-Ile8-A II at the rabbit aorta angiotensin II receptor, type 11993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
AID197551Percentage peak pressor response in rat after intravenous administration at a dose of 0.3 mg/kg of the compound.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.
AID39022Binding affinity against angiotensin II receptor from rat liver1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
AID39524In vitro binding affinity for angiotensin II AT2 receptor in rat midbrain1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
A highly potent, orally active imidazo[4,5-b]pyridine biphenylacylsulfonamide (MK-996; L-159,282): a new AT1-selective angiotensin II receptor antagonist.
AID15485Cmax value after oral dose of 3.87 mg/kg1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's70 (53.03)18.2507
2000's52 (39.39)29.6817
2010's10 (7.58)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other133 (97.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]